|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: GAPDH |
Gene summary for GAPDH |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | GAPDH | Gene ID | 2597 |
| Gene name | glyceraldehyde-3-phosphate dehydrogenase | |
| Gene Alias | G3PD | |
| Cytomap | 12p13.31 | |
| Gene Type | protein-coding | GO ID | GO:0000226 | UniProtAcc | P04406 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 2597 | GAPDH | GSM4909280 | Human | Breast | Precancer | 3.61e-03 | -5.09e-01 | 0.0305 |
| 2597 | GAPDH | GSM4909282 | Human | Breast | IDC | 1.93e-89 | 4.84e-01 | -0.0288 |
| 2597 | GAPDH | GSM4909285 | Human | Breast | IDC | 3.37e-57 | 4.02e-01 | 0.21 |
| 2597 | GAPDH | GSM4909287 | Human | Breast | IDC | 4.59e-33 | 2.99e-01 | 0.2057 |
| 2597 | GAPDH | GSM4909288 | Human | Breast | IDC | 1.84e-12 | 3.45e-01 | 0.0988 |
| 2597 | GAPDH | GSM4909296 | Human | Breast | IDC | 2.35e-06 | 8.43e-02 | 0.1524 |
| 2597 | GAPDH | GSM4909297 | Human | Breast | IDC | 2.99e-06 | -7.00e-02 | 0.1517 |
| 2597 | GAPDH | GSM4909298 | Human | Breast | IDC | 5.91e-10 | -1.73e-01 | 0.1551 |
| 2597 | GAPDH | GSM4909299 | Human | Breast | IDC | 1.22e-14 | -1.98e-01 | 0.035 |
| 2597 | GAPDH | GSM4909301 | Human | Breast | IDC | 4.21e-10 | -2.84e-01 | 0.1577 |
| 2597 | GAPDH | GSM4909302 | Human | Breast | IDC | 6.05e-05 | 3.97e-02 | 0.1545 |
| 2597 | GAPDH | GSM4909303 | Human | Breast | IDC | 1.02e-02 | -3.18e-01 | 0.0438 |
| 2597 | GAPDH | GSM4909304 | Human | Breast | IDC | 3.48e-03 | 1.22e-01 | 0.1636 |
| 2597 | GAPDH | GSM4909308 | Human | Breast | IDC | 4.79e-03 | 1.44e-01 | 0.158 |
| 2597 | GAPDH | GSM4909311 | Human | Breast | IDC | 4.76e-21 | -1.62e-01 | 0.1534 |
| 2597 | GAPDH | GSM4909315 | Human | Breast | IDC | 2.31e-95 | 5.93e-01 | 0.21 |
| 2597 | GAPDH | GSM4909316 | Human | Breast | IDC | 2.91e-31 | 4.52e-01 | 0.21 |
| 2597 | GAPDH | GSM4909318 | Human | Breast | IDC | 7.67e-07 | 2.76e-01 | 0.2031 |
| 2597 | GAPDH | GSM4909319 | Human | Breast | IDC | 8.74e-55 | 9.67e-02 | 0.1563 |
| 2597 | GAPDH | GSM4909320 | Human | Breast | IDC | 3.56e-07 | -4.80e-01 | 0.1575 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00460349 | Breast | Precancer | ATP metabolic process | 82/1080 | 277/18723 | 1.94e-36 | 5.19e-33 | 82 |
| GO:00060918 | Breast | Precancer | generation of precursor metabolites and energy | 94/1080 | 490/18723 | 1.54e-25 | 1.64e-22 | 94 |
| GO:00525479 | Breast | Precancer | regulation of peptidase activity | 71/1080 | 461/18723 | 2.72e-14 | 6.94e-12 | 71 |
| GO:00525489 | Breast | Precancer | regulation of endopeptidase activity | 67/1080 | 432/18723 | 1.06e-13 | 2.36e-11 | 67 |
| GO:00064179 | Breast | Precancer | regulation of translation | 67/1080 | 468/18723 | 4.71e-12 | 7.64e-10 | 67 |
| GO:00458619 | Breast | Precancer | negative regulation of proteolysis | 50/1080 | 351/18723 | 2.99e-09 | 2.39e-07 | 50 |
| GO:00709979 | Breast | Precancer | neuron death | 50/1080 | 361/18723 | 7.75e-09 | 5.70e-07 | 50 |
| GO:00514029 | Breast | Precancer | neuron apoptotic process | 38/1080 | 246/18723 | 2.68e-08 | 1.75e-06 | 38 |
| GO:00444039 | Breast | Precancer | biological process involved in symbiotic interaction | 42/1080 | 290/18723 | 3.40e-08 | 2.11e-06 | 42 |
| GO:00513468 | Breast | Precancer | negative regulation of hydrolase activity | 50/1080 | 379/18723 | 3.85e-08 | 2.34e-06 | 50 |
| GO:00104668 | Breast | Precancer | negative regulation of peptidase activity | 38/1080 | 262/18723 | 1.46e-07 | 7.82e-06 | 38 |
| GO:00109519 | Breast | Precancer | negative regulation of endopeptidase activity | 37/1080 | 252/18723 | 1.55e-07 | 8.05e-06 | 37 |
| GO:00196938 | Breast | Precancer | ribose phosphate metabolic process | 49/1080 | 396/18723 | 3.81e-07 | 1.78e-05 | 49 |
| GO:00091509 | Breast | Precancer | purine ribonucleotide metabolic process | 46/1080 | 368/18723 | 6.47e-07 | 2.71e-05 | 46 |
| GO:00091179 | Breast | Precancer | nucleotide metabolic process | 56/1080 | 489/18723 | 7.40e-07 | 3.00e-05 | 56 |
| GO:00092598 | Breast | Precancer | ribonucleotide metabolic process | 47/1080 | 385/18723 | 9.69e-07 | 3.84e-05 | 47 |
| GO:00469398 | Breast | Precancer | nucleotide phosphorylation | 20/1080 | 101/18723 | 1.07e-06 | 4.18e-05 | 20 |
| GO:00067539 | Breast | Precancer | nucleoside phosphate metabolic process | 56/1080 | 497/18723 | 1.24e-06 | 4.70e-05 | 56 |
| GO:00508219 | Breast | Precancer | protein stabilization | 29/1080 | 191/18723 | 1.67e-06 | 6.08e-05 | 29 |
| GO:00061639 | Breast | Precancer | purine nucleotide metabolic process | 47/1080 | 396/18723 | 2.14e-06 | 7.50e-05 | 47 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0501016 | Breast | Precancer | Alzheimer disease | 103/684 | 384/8465 | 1.03e-29 | 4.66e-28 | 3.57e-28 | 103 |
| hsa0541518 | Breast | Precancer | Diabetic cardiomyopathy | 63/684 | 203/8465 | 5.63e-22 | 1.48e-20 | 1.14e-20 | 63 |
| hsa0513218 | Breast | Precancer | Salmonella infection | 49/684 | 249/8465 | 2.92e-09 | 6.15e-08 | 4.71e-08 | 49 |
| hsa0513018 | Breast | Precancer | Pathogenic Escherichia coli infection | 38/684 | 197/8465 | 3.12e-07 | 5.81e-06 | 4.45e-06 | 38 |
| hsa0406616 | Breast | Precancer | HIF-1 signaling pathway | 23/684 | 109/8465 | 1.51e-05 | 1.59e-04 | 1.22e-04 | 23 |
| hsa0001010 | Breast | Precancer | Glycolysis / Gluconeogenesis | 13/684 | 67/8465 | 2.39e-03 | 1.51e-02 | 1.16e-02 | 13 |
| hsa0120012 | Breast | Precancer | Carbon metabolism | 18/684 | 115/8465 | 4.79e-03 | 2.75e-02 | 2.11e-02 | 18 |
| hsa0501017 | Breast | Precancer | Alzheimer disease | 103/684 | 384/8465 | 1.03e-29 | 4.66e-28 | 3.57e-28 | 103 |
| hsa0541519 | Breast | Precancer | Diabetic cardiomyopathy | 63/684 | 203/8465 | 5.63e-22 | 1.48e-20 | 1.14e-20 | 63 |
| hsa0513219 | Breast | Precancer | Salmonella infection | 49/684 | 249/8465 | 2.92e-09 | 6.15e-08 | 4.71e-08 | 49 |
| hsa0513019 | Breast | Precancer | Pathogenic Escherichia coli infection | 38/684 | 197/8465 | 3.12e-07 | 5.81e-06 | 4.45e-06 | 38 |
| hsa0406617 | Breast | Precancer | HIF-1 signaling pathway | 23/684 | 109/8465 | 1.51e-05 | 1.59e-04 | 1.22e-04 | 23 |
| hsa0001013 | Breast | Precancer | Glycolysis / Gluconeogenesis | 13/684 | 67/8465 | 2.39e-03 | 1.51e-02 | 1.16e-02 | 13 |
| hsa0120013 | Breast | Precancer | Carbon metabolism | 18/684 | 115/8465 | 4.79e-03 | 2.75e-02 | 2.11e-02 | 18 |
| hsa0501023 | Breast | IDC | Alzheimer disease | 107/867 | 384/8465 | 1.70e-23 | 7.88e-22 | 5.90e-22 | 107 |
| hsa0541523 | Breast | IDC | Diabetic cardiomyopathy | 67/867 | 203/8465 | 3.17e-19 | 8.59e-18 | 6.43e-18 | 67 |
| hsa0513224 | Breast | IDC | Salmonella infection | 55/867 | 249/8465 | 2.07e-08 | 4.49e-07 | 3.36e-07 | 55 |
| hsa0513024 | Breast | IDC | Pathogenic Escherichia coli infection | 42/867 | 197/8465 | 2.66e-06 | 3.92e-05 | 2.94e-05 | 42 |
| hsa0406623 | Breast | IDC | HIF-1 signaling pathway | 22/867 | 109/8465 | 1.36e-03 | 1.00e-02 | 7.50e-03 | 22 |
| hsa0501033 | Breast | IDC | Alzheimer disease | 107/867 | 384/8465 | 1.70e-23 | 7.88e-22 | 5.90e-22 | 107 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| GAPDH | SNV | Missense_Mutation | c.658N>C | p.Val220Leu | p.V220L | P04406 | protein_coding | deleterious_low_confidence(0.01) | benign(0.409) | TCGA-A2-A25B-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | PD | |
| GAPDH | SNV | Missense_Mutation | novel | c.550A>G | p.Thr184Ala | p.T184A | P04406 | protein_coding | deleterious_low_confidence(0) | benign(0.1) | TCGA-A8-A07U-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | 5-fluorouracil | SD |
| GAPDH | insertion | Frame_Shift_Ins | novel | c.536_537insT | p.Ala180CysfsTer19 | p.A180Cfs*19 | P04406 | protein_coding | TCGA-AN-A0FN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| GAPDH | insertion | In_Frame_Ins | novel | c.538_539insCCCTTCTCCCCATTCCGTCTT | p.Ala180_Ile181insLeuLeuProIleProSerSer | p.A180_I181insLLPIPSS | P04406 | protein_coding | TCGA-AN-A0FN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| GAPDH | insertion | Frame_Shift_Ins | novel | c.322_323insGGTGGGCTTGCCCTGTCCAGTTAATTTCTGAC | p.Ala108GlyfsTer39 | p.A108Gfs*39 | P04406 | protein_coding | TCGA-B6-A0RE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| GAPDH | SNV | Missense_Mutation | c.274N>A | p.Ala92Thr | p.A92T | P04406 | protein_coding | deleterious_low_confidence(0.03) | benign(0.07) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| GAPDH | SNV | Missense_Mutation | c.599N>T | p.Arg200Leu | p.R200L | P04406 | protein_coding | tolerated_low_confidence(0.06) | benign(0.068) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD | |
| GAPDH | SNV | Missense_Mutation | c.306C>G | p.Phe102Leu | p.F102L | P04406 | protein_coding | deleterious_low_confidence(0.01) | possibly_damaging(0.805) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| GAPDH | SNV | Missense_Mutation | novel | c.887A>G | p.Asp296Gly | p.D296G | P04406 | protein_coding | deleterious_low_confidence(0.01) | benign(0.423) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| GAPDH | SNV | Missense_Mutation | c.266N>G | p.Asp89Gly | p.D89G | P04406 | protein_coding | deleterious_low_confidence(0.02) | possibly_damaging(0.615) | TCGA-AP-A0LP-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Hormone Therapy | megace | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 2597 | GAPDH | DRUGGABLE GENOME, ENZYME | PURPUROGALLIN | PURPUROGALLIN | ||
| 2597 | GAPDH | DRUGGABLE GENOME, ENZYME | NSC-228155 | CHEMBL505670 | ||
| 2597 | GAPDH | DRUGGABLE GENOME, ENZYME | NSC-92207 | CHEMBL139935 | ||
| 2597 | GAPDH | DRUGGABLE GENOME, ENZYME | NSC-119911 | CHEMBL502775 | ||
| 2597 | GAPDH | DRUGGABLE GENOME, ENZYME | BISPHOSPHONATES | 8518293 | ||
| 2597 | GAPDH | DRUGGABLE GENOME, ENZYME | NSC-95397 | CHEMBL429095 | ||
| 2597 | GAPDH | DRUGGABLE GENOME, ENZYME | TCMDC-124224 | CHEMBL580421 | ||
| 2597 | GAPDH | DRUGGABLE GENOME, ENZYME | Omigapil | OMIGAPIL | ||
| 2597 | GAPDH | DRUGGABLE GENOME, ENZYME | 9,10-PHENANTHRENEQUINONE | 9,10-PHENANTHRENEQUINONE | ||
| 2597 | GAPDH | DRUGGABLE GENOME, ENZYME | ANESTHETICS | 17194030 |
| Page: 1 2 3 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |